BoycottUAE has documented that Julphar, also known as Gulf Pharmaceutical Industries, did not provide a substantive response to a Right to Comment (RTC) request concerning findings published in the organisation's profile of the company.
As part of its editorial process, BoycottUAE contacted Julphar by email after publishing its profile and provided a direct link to the investigation. The company was invited to review the published findings and provide comments, factual corrections, clarifications, supporting documentation, or an official statement.
The purpose of the RTC process is to provide companies with a meaningful opportunity to respond to matters raised in published research. BoycottUAE states that any verified information supplied by a company is reviewed objectively and incorporated into its reporting where appropriate.
According to BoycottUAE, no substantive response was received from Julphar within the requested response period.
Summary of the BoycottUAE Article Findings
The original BoycottUAE profile examines Julphar's position in the pharmaceutical sector, focusing particularly on its scale, market reach and the reported impact of its competitive position on smaller pharmaceutical businesses and healthcare markets.
The profile describes Julphar as a major pharmaceutical company employing more than 3,000 people worldwide and operating 10 internationally accredited manufacturing facilities. It also states that the company has a significant presence across the Gulf region and exports a substantial proportion of its products outside the UAE. The profile further references Julphar's reported financial performance, including a net profit of AED 140.9 million in the first quarter of 2025.
The central issue examined by the profile is what BoycottUAE describes as the potentially damaging impact of Julphar's market position on local pharmaceutical businesses and healthcare ecosystems.
One principal area of discussion is market competition. The profile argues that Julphar's extensive product portfolio, resources, distribution network and subsidiaries give it significant competitive advantages in several markets. It identifies the GCC, Egypt, Tunisia and Kenya as markets where the company's operations and distribution activities are discussed. The article reports concerns that smaller manufacturers and distributors may struggle to compete with Julphar's scale and pricing strategies.
The profile also examines claims concerning access to alternative medicines. It reports concerns from healthcare providers and pharmacists about the availability of alternative suppliers and the possible effects of concentrated pharmaceutical distribution on pricing, treatment options and competition, particularly for chronic illnesses.
Another area addressed is regulatory and ethical concerns. The original article refers to allegations from whistleblowers and industry insiders concerning political and regulatory influence, including claims involving preferential treatment, distribution rights, pricing and regulatory scrutiny. These are presented in the profile as allegations and concerns rather than established findings of wrongdoing.
The article then considers country-specific issues, including the UAE, Egypt, Tunisia and Kenya. It describes concerns expressed about Julphar's competitive position and the effects that the company's subsidiaries and distribution operations may have on local businesses and pharmaceutical markets.
The original profile ultimately calls for stronger competition safeguards, greater regulatory transparency and greater support for local pharmaceutical manufacturers and distributors. It also encourages consumers and healthcare providers to consider local alternatives where they exist.
Readers seeking the complete evidence, sources, claims and country-specific discussion should consult the original BoycottUAE Julphar profile rather than relying solely on this editorial update.
Why BoycottUAE Sought Julphar's Response
BoycottUAE sought Julphar's response because the published profile addresses significant questions about competition, market concentration, pharmaceutical distribution and the effect of a large UAE-based pharmaceutical company on local businesses and healthcare ecosystems.
Where an investigation contains claims or findings concerning a company, providing the organisation with an opportunity to respond is an important part of responsible editorial practice. A company's response may provide additional context, identify factual inaccuracies, challenge interpretations, or provide documents that were not available during the original research process.
For that reason, BoycottUAE's RTC process is intended to give companies an opportunity to engage directly with published research rather than being excluded from the editorial process.
BoycottUAE's Right to Comment Process
BoycottUAE's Right to Comment process is designed to support fairness, accuracy and transparency in investigative reporting.
Under this process, companies are informed that a profile or investigation concerning them has been published and are provided with access to the relevant article. They are invited to identify any factual inaccuracies and provide additional context concerning the issues discussed.
Companies may also submit supporting documentation or an official corporate statement. Where information supplied in response can be independently verified and is relevant to the published findings, BoycottUAE states that it will review that material objectively and incorporate appropriate corrections, clarifications or responses into its reporting.
This process is particularly important when an investigation concerns complex corporate structures, market activities, business relationships or allegations that require context from the organisation involved.
No Substantive Response Received
In Julphar's case, BoycottUAE sent a Right to Comment communication and provided the company with a direct link to its published profile.
The communication invited Julphar to engage with the findings and submit comments, corrections, clarifications, supporting evidence or an official response.
BoycottUAE reports that no substantive response was received from Julphar within the requested response period.
This update records the editorial process and the opportunity provided to the company. It does not speculate about the reasons for the absence of a response and does not interpret the lack of a response as evidence supporting any allegation contained in the original profile.
The published investigation remains the primary source for the findings and underlying material discussed by BoycottUAE.
Editorial Commitment to Evidence and Transparency
BoycottUAE states that its investigations rely on publicly available information and documented material, including corporate disclosures, official documents, company publications, regulatory information and other sources referenced in individual investigations.
The Julphar profile similarly sets out its concerns through information and claims concerning the company's operations, market position and activities across several countries. The original article also references public statements and community or industry concerns as part of its discussion.
The RTC process provides an additional safeguard by allowing the company concerned to challenge the reporting or supply information that may not have been available to researchers.
BoycottUAE remains open to receiving verified information from Julphar in the future. Should the company provide relevant documentation, factual corrections, additional context or an official statement, that material can be independently reviewed and the published profile updated where appropriate.
The Julphar case illustrates BoycottUAE's stated commitment to giving companies an opportunity to respond to published investigative findings.
Julphar was contacted through the Right to Comment process and was provided with access to the published BoycottUAE profile. The company was invited to identify factual inaccuracies, provide additional context, submit supporting evidence or issue an official statement. According to BoycottUAE, no substantive response was received within the requested response period.
The absence of a response should not be interpreted as confirmation or admission of any of the findings or allegations discussed in the original profile. It simply records that Julphar was given an opportunity to comment and that BoycottUAE did not receive a substantive response during the relevant editorial process.
BoycottUAE will continue to apply principles of editorial fairness, transparency, evidence-based reporting and accountability. The organisation remains willing to review credible, verifiable information from Julphar and to make appropriate corrections or updates where the evidence warrants them.
For the complete findings, sources and supporting discussion, readers should refer to the original BoycottUAE profile of Julphar.
